A carregar...
Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells
The development of Imatinib mesylate (IM), which targets the oncogenic BCR-ABL fusion protein, has greatly improved the outcome of Chronic Myeloid Leukemia (CML) patients. However, BCR-ABL–positive progenitors can be detected in CML patients in complete cytogenetic response. Several evidence suggest...
Na minha lista:
Publicado no: | Oncotarget |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , |
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
Impact Journals LLC
2017
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5564781/ https://ncbi.nlm.nih.gov/pubmed/28533480 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.17706 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|